Philippines Certificate of Free Sale: Source, Content and Authentication

1. Key takeaways

Yes, it is required. Philippine registration requires proof that the device is lawfully marketed in its country of origin or in a reference market, which in practice takes the form of a CFS (Certificate of Free Sale). The CFS should be issued by the regulatory authority of the country of origin or of the reference market — Chinese manufacturers normally obtain it from the National Medical Products Administration or the provincial drug regulatory department — and it must go through notarisation followed by Apostille.

GRZAN note: the CFS is a short document that carries a disproportionate amount of weight, because it is the single item that connects the declared product to a real market somewhere else in the world. The requirement can be remembered as 2 permissible sources, 4 content failures that void the certificate, and 1 fixed sequence of authentication.

• CFS issued by the authority of the country of origin or the reference market;
• Product name and model must match the declared device;
• Manufacturer name and address must match the LOA and the ISO 13485 certificate;
• Notarisation first, Apostille second.

The reason this document causes so much friction is that it is produced by a third party outside the company’s own control. A manufacturer can revise its own technical file in a week, but obtaining a corrected certificate from a regulator takes as long as that regulator takes, which is why the content check has to happen at the moment of issue rather than at the moment of filing.

2. Legal basis

The origin requirement, its definition in the order and the authentication route are summarised below. The definition is deliberately broad, and the breadth is the point: it allows a device to be anchored either to where it is made or to where it has already been authorised.

3. Expert insights

Insight 1: the dual definition of country of origin gives companies a choice. Section IV item 8 defines the country of origin either as the country of manufacture or as a country in which the device was registered or granted marketing approval before distribution to the Philippines. Two sources are therefore available. Where a product does not yet hold lawful marketing authorisation in China, for example because it is manufactured for export only, the certificate can instead be obtained from a reference market where approval already exists, such as the European Union, the United States or an ASEAN member state. That choice is commercially valuable and is often overlooked, particularly by exporters whose domestic registration is still pending or who manufacture exclusively for export markets.

Insight 2: the usual failure mode is incomplete content rather than forgery. Four categories account for most rejected certificates: the product name and model are absent or do not match the declared device; the manufacturer name and address are absent or do not match the LOA and the ISO 13485 certificate; the issuing authority seal or the issue date is missing; or the certificate has passed its validity period, since some countries issue a CFS with a limited term such as 2 years. The consequence is not a deficiency notice but the return of the entire application.

Insight 3: the CFS and the evidence for the Abridged pathway are two different things. The CFS proves lawful sale in the country of origin or a reference country. The Abridged pathway requires approval issued by an ASEAN member state NRA on the basis of the AMDD-CSDT. The latter is a higher bar: it must be an ASEAN member state approval, and it must rest on the CSDT. Holding a US 510(k) or an EU CE mark can support a CFS, but cannot substitute for the eligibility evidence required by the Abridged route. This distinction is frequently blurred in secondary summaries, and the blurring has real consequences: a company that assumes its CE mark establishes Abridged eligibility may plan a thirty-working-day timeline that it is not entitled to.

Insight 4: the CFS itself must be notarised and apostilled. Like the LOA, the CFS is a document issued abroad and must first be converted into a public document by notarisation and then receive an Apostille. Since 7 November 2023 China and the Philippines recognise Apostilles reciprocally, so consular legalisation is no longer required. The order still matters: notarisation first, Apostille second.

4. Practical recommendations

• Decide the source country for the CFS early. Where the device is not yet marketed in China, prefer a reference market that has already granted approval.
• Verify the four content items. Product name and model, manufacturer name and address, issuing authority seal and date, and validity.
• Cross-check three documents. The manufacturer name and product name must agree across the CFS, the LOA and the ISO 13485 certificate.
• Notarise before applying for the Apostille, and start 4 to 6 weeks ahead.

Taken together, these steps treat the CFS as a document with two independent failure modes: content that does not match the rest of the file, and authentication that is out of sequence. Either one is fatal on its own, and neither can be corrected quickly once the application has been lodged.

5. Verification checklist

• □ CFS source country compliant: country of origin or a reference market where approval already exists
• □ Product name and model consistent with the declared device
• □ Manufacturer name and address consistent with the LOA and ISO 13485 certificate
• □ Issuing authority seal legible and issue date stated
• □ Certificate within its validity period
• □ Notarisation and Apostille completed, originals held and verifiable online

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including the Philippines. Our team prepares CMDN/CMDR dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the FDA Philippines, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com